Venetoclax + hypomethylating agent
Azacitidine primes leukaemia cells for death; venetoclax removes the BCL-2 shield. Together they roughly doubled remissions in older AML.
VIALE-A: OS 14.7 vs 9.6 months, CR 36.7% vs 17.9%. Now available fully orally (Inqovi + venetoclax, 2026). Duration of venetoclax (14 vs 28 days) is being shortened to reduce cytopenias without losing efficacy.
Pages like this
not linked directly; found by shared links- IdeaShorter venetoclax courses in unfit AML
Shares Decitabine + cedazuridine (oral), VIALE-A, Azacitidine, Venetoclax.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.
- Key paperAGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.
- CompanyTaiho Oncology (Otsuka)
Shares Decitabine + cedazuridine (oral), Acute myeloid leukaemia.
- TermTumour lysis syndrome (TLS)
Shares VIALE-A, Venetoclax, Acute myeloid leukaemia.
- TermHypomethylating agents (azacitidine, decitabine)
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.
- PersonAnthony Letai
Shares Intrinsic apoptosis (BCL-2 family), Venetoclax, Acute myeloid leukaemia.
- Term7+3 induction chemotherapy
Shares Azacitidine, Venetoclax, Acute myeloid leukaemia.